mTOR signaling for biological control and cancer
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Mammalian target of rapamycin (mTOR) is a major intersection that connects signals from the extracellular milieu to corresponding changes in intracellular processes. When abnormally regulated, the mTOR signaling pathway is implicated in a wide spectrum of cancers, neurological diseases, and proliferative disorders. Therefore, pharmacological agents that restore the regulatory balance of the mTOR pathway could be beneficial for a great number of diseases. This review summarizes current understanding of mTOR signaling and some unanswered questions in the field. We describe the composition of the mTOR complexes, upstream signals that activate mTOR, and physiological processes that mTOR regulates. We also discuss the role of mTOR and its downstream effectors in cancer, obesity and diabetes, and autism. J. Cell. Physiol. 228: 1658–1664, 2013. © 2013 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · cited 1×
“Calorie restricting lifestyle extends lifespan and delays onset of age-related diseases in many different species from yeast to humans, and the mTOR signaling pathway is highly involved in the regulation of this process (Fontana et al., 2004, 2010; Harrison et al., 2009).”
BackgroundExtending Healthy Life Span—From Yeast to Humans
Fontana, L., Partridge, L., & Longo, V. D. (2010) · Science · doi:10.1126/science.1172539 · Cited by 3,023 · cited 1×
“Calorie restricting lifestyle extends lifespan and delays onset of age-related diseases in many different species from yeast to humans, and the mTOR signaling pathway is highly involved in the regulation of this process (Fontana et al., 2004, 2010; Harrison et al., 2009).”
BackgroundEverolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · cited 1×
“This positive co-regulatory loop between the mTORC1/S6K1 and ERa signaling explains the success of the combination therapy targeting these two JOURNAL OF CELLULAR PHYSIOLOGY pathways in hormone-positive breast cancer (Baselga et al., 2009; Baselga et al., 2012).”
BackgroundThe Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L., & Sabatini, D. M. (2008) · Science · doi:10.1126/science.1157535 · Cited by 2,773 · cited 2×
“Rag proteins bind to Raptor in an amino acid-sensitive manner and activate mTORC1 by localizing it to the cytosolic side of the lysosomal membranes, where it interacts with Rheb (Smith et al., 2005; Sancak et al., 2010).”
BackgroundSarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
Sancak, Y., Bar-Peled, L., Zoncu, R., Markhard, A. L., Nada, S., & Sabatini, D. M. (2010) · Cell · doi:10.1016/j.cell.2010.02.024 · Cited by 2,464 · cited 1×
“…compounded by the fact that there are no known specific inhibitors of mTORC2. mTORC2 is characterized by association with rictor, a binding partner for mTOR, whose interaction is mutually exclusive with that of raptor, a binding partner of mTORC1 (Jacinto et al., 2004; Sarbassov et al., 2004).”
BackgroundA mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053
Activation of a metabolic gene regulatory network downstream of mTOR complex 1
Düvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.022 · Cited by 2,020 · cited 1×
“Once active, SREBP-1 translocates to the nucleus where it binds to promoters of genes containing sterol regulatory elements and Enhancer Box sequences. mTORC1 is thought to activate SREBP-1 through S6K1 by promoting posttranslational processing (Duvel et al., 2010).”
Background
Cited by
Perluigi, M., Di Domenico, F., & Butterfield, D. A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.03.014 · Cited by 339
Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease
Golpich, M., Amini, E., Hemmati, F., Ibrahim, N. M., Rahmani, B., Mohamed, Z., Raymond, A. A., Dargahi, L., Ghasemi, R., & Ahmadiani, A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.03.010 · Cited by 276
Liu, P., Gan, W., Inuzuka, H., Lazorchak, A. S., Gao, D., Arojo, O., Liu, D., Wan, L., Zhai, B., Yu, Y., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2860 · Cited by 259
Blumcke, I., Aronica, E., Urbach, H., Alexopoulos, A., & Gonzalez-Martinez, J. A. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1288-9 · Cited by 179
“The mTOR pathway acts as key regulator of cell size and growth control, proliferation, differentiation and survival during brain development, and increasing evidence supports the role of the TOR pathway in a wide variety of neurological disorders including both MCD and brain tumors [1, 23, 26, 96].”
BackgroundOvernutrition, mTOR signaling, and cardiovascular diseases
Jia, G., Aroor, A. R., Martinez-Lemus, L. A., & Sowers, J. R. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00262.2014 · Cited by 122
“Inhibition of mTORC1 activity is also promoted by increases in hypoxia-inducible transcription factor-1 (HIF1) ␣ and , which enhance the expression of regulated in development and DNA damage response-1 (REDD1) and REDD2 (2).”
InfluentialMartínez-Cerdeño, V., Camacho, J., Fox, E., Miller, E., Ariza, J., Kienzle, D., Plank, K., Noctor, S. C., & Van de Water, J. (2016) · Cerebral Cortex · doi:10.1093/cercor/bhu291 · Cited by 63
“In addition, altered expression of genes that regulate cell size, such as mTOR, have been implicated in ASD (Garcia-Penas and Carreras-Saaez 2013) and are reflected in changes in cell morphology and cognitive functioning (Alayev and Holz 2013).”
Background
Metadata
- Authors
- Alayev, A., & Holz, M. K.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2013-04-18
- Volume
- 228
- Issue
- 8
- Pages
- 1658-1664
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2025452473
- Cited by
- 138
- References
- 42
- FWCI
- 9.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.